The CCR9 Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population targeting the CCR9 gene in HT29 colorectal adenocarcinoma cells. This loss-of-function model facilitates investigation of CCR9’s role in chemokine signaling and intestinal epithelial biology. The polyclonal nature provides a heterogeneous gene-disrupted pool suitable for reproducible functional studies without transient knockdown limitations.
The HT29 cell line, derived from a primary colorectal adenocarcinoma of a 44-year-old female, is a well-established intestinal epithelial model. These cells retain differentiated functions such as mucus production and polarization, making them ideal for studying gut-specific pathways. Their colorectal adenocarcinoma origin provides a physiologically relevant context for examining CCR9-mediated processes in intestinal pathophysiology.
CCR9 encodes a G protein-coupled receptor for the chemokine CCL25 (TECK), crucial for lymphocyte homing to the gut. Ligand binding activates Gi, Gq, and G12/13 proteins, triggering PLC-??-mediated calcium mobilization and downstream MAPK/ERK (Ras-Raf-MEK-ERK) and PI3K-Akt cascades. CCR9 also recruits ??-arrestin-2 and GRK2 for signal regulation. These pathways lead to NF-??B and AP-1 transcription factor activation, Rho/Rac GTPase-mediated cytoskeletal changes, and integrin ??4??7 upregulation, thereby controlling directed migration, survival, and gene expression in intestinal immunity.
In HT29 cells, CCR9 signaling may influence tumor cell migration, invasion, and immune microenvironment interactions. Knocking out CCR9 enables dissection of its role in colorectal cancer progression and inflammatory bowel disease-related pathways. This model allows researchers to isolate CCL25/CCR9-driven signaling and crosstalk with other chemokine axes, clarifying how CCR9 integrates into epithelial cell networks controlling intestinal homeostasis and disease.
This knockout population supports diverse research applications, including drug target validation, migration/invasion assays (Boyden chamber), calcium flux analysis, phospho-ERK/Akt detection, and RhoA/Rac activation assays. It is suitable for co-culture with immune cells, RNA-seq profiling, and high-throughput screening. The polyclonal format ensures robust and reproducible results for mechanistic studies and pathway interrogation. For further inquiries, please contact Ascent Research.
